References
- Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 379, 1447–1456 (2012).
- Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem. Pharmacol. 82, 91–98 (2011).
- Hermans C, Brackmann HH, Schinco P, Auerswald G. The case for wider use of recombinant factor VIII concentrates. Crit. Rev. Oncol. Hematol. 83, 11–20 (2012).
- Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 14, 671–684 (2008).
- Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 16, 66–70 (2010).
- Green D. Factor VIII inhibitors: a 50-year perspective. Haemophilia 17, 831–838 (2011).
- Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med. 368, 231–239 (2013).
- Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 119, 4108–4114 (2012).
- Tarantino MD, Ye X, Bergstrom F, Skorija K, Luo MP. The impact of the economic downturn and health care reform on treatment decisions for haemophilia A: patient, caregiver and health care provider perspectives. Haemophilia 19, 51–58 (2013).
- Skinner MW. Gene therapy for hemophilia: Addressing the coming challenges of affordability and accessibility. Mol. Ther. 21, 1–2 (2013).
- Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review. Crit. Rev. Oncol. Hematol. 81, 82–93 (2012).
- Kamar N, Bendall R, Legrand-Abravanel F et al. Hepatitis E. Lancet 379, 2477–2488 (2012).
- Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 142, 1388–1397 (2012).
- Andréoletti O, Litaise C, Simmons H et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog. 8, e1002782 (2012).
- Zaman SMA, Hill FGH, Palmer B et al. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia 17, 931–937 (2011).
- Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 120, 720–727 (2012).
- Arrieta R, Altisent C, Álvarez T et al. Hemophilia: Therapeutic Guidelines (1st Edition). Ministry of Health, Social Services and Equality of Spain, Madrid (2012).
- De Mendoza C, Altisent C, Aznar JA, Batlle J, Soriano V. Emerging viral infections – a potential threat for blood supply in the 21st century. AIDS Rev. 14, 279–289 (2012).